Lowering of Blood Ammonia Level Following Administration of Yeast Glutamate Dehydrogenase in Dogs with Porto Caval Anastomosis

Pharmacology ◽  
1965 ◽  
Vol 12 (4) ◽  
pp. 233-238
Author(s):  
C.L. Quijada ◽  
P.M. Goñi
Keyword(s):  
Glutamate Dehydrogenase ◽  
Ammonia Level ◽  
Blood Ammonia ◽  
Blood Ammonia Level

scholarly journals High Blood Ammonia Levels Associated with Long-term Valproic Acids Therapy in Epileptic Children

2020 ◽  
Vol 4 (2) ◽  
pp. 83
Author(s):  
I Gusti Lanang Sidiartha ◽  
I Gusti Ngurah Made Suwarba ◽  
Dyah Kanya Wati ◽  
Ida Bagus Subanada
Keyword(s):  
Valproic Acid ◽  
Combination Therapy ◽  
Ammonia Level ◽  
Blood Ammonia ◽  
Cross Sectional ◽  
Acid Therapy ◽  
Blood Ammonia Level ◽  
Significant Difference ◽  
Epileptic Children

Background: Valproic acid is an effective drug for controlling seizure in children with epilepsy and it is usually used for treatment as long as two years or more. Blood ammonia level often increased in epileptic children who were treated with long-term valproic acid. The study was conducted to determine the relationship between blood ammonia level with valproic acid therapy in epileptic children.Materials and Methods: This is an observational study with cross-sectional approach. The subjects were 64 children with epilepsy, average age of 6.2 years old. Subjects were 33 boys and 31 girls. Blood ammonia level was examined using enzymatic glutamate dehydrogenase. Subjects were divided into 2 therapeutic groups based on the duration, doses and combination therapy of valproic acid. Subjects were recruited from Pediatric Neurology Clinic, Sanglah General Hospital, Bali, Indonesia, from May to December 2017. Comparison of blood ammonia level between groups were analyzed using an Independent t-test with significances if the p<0.05. Results: A significant difference of blood ammonia level was found between subjects who were treated with valproic acid less than 2 years and more than 2 years (45.7±16.4 mmol/L vs. 70.9±43.6 mmol/L; p=0.032). However, significant difference was not found between the groups according to the doses and combination therapy (p=0.450 and p=0.647, respectively).Conclusion: Blood ammonia level was significantly higher in epileptic children who used long-term valproic acid, hence it was recommended to check the blood ammonia level routinely.Keywords: ammonia, epilepsy, valproic, children

The Effect of Cisplatin on Blood Ammonia Elevation by Alanyl-Glutamine Supplementation

Pharmacology ◽  
2018 ◽  
Vol 101 (3-4) ◽  
pp. 156-162
Author(s):  
Yoko Obayashi ◽  
Kenta Kajiwara ◽  
Eiji Nakamura
Keyword(s):  
Beneficial Effect ◽  
Intravenous Infusion ◽  
Ammonia Level ◽  
Glutamine Supplementation ◽  
Glutamic Pyruvic Transaminase ◽  
Elevated Blood ◽  
Blood Ammonia ◽  
Renal Disorder ◽  
Blood Ammonia Level ◽  
Glutamate Oxaloacetic Transaminase

Background: Although there are many clinical studies in which the beneficial effect of glutamine formulation on mucositis induced by chemo/radiotherapy was evaluated, the results are sometimes conflicting with the report of clinical deterioration. Then, we hypothesized that chemotherapy may increase the incidence of hyperammonemia without comparable change of major parameters of hepatic/renal disorder. Methods: To verify our hypothesis, we examined the increase in blood ammonia level with 1-h intravenous infusion of alanyl-glutamine on day 1–4 after cisplatin (CDDP) administration in rats and assessed the correlation with hepatic/renal parameters. Results: Hepatic parameters (glutamate-oxaloacetic transaminase [GOT] and glutamic-pyruvic transaminase [GPT]) with CDDP did not change until day 3 and only GOT increased on day 4. Renal parameters (plasma creatinine, blood urea nitrogen) with CDDP continuously increased up to day 4. Alanyl-glutamine infusion significantly elevated blood ammonia level of CDDP rats with the peak on day 3, although the same dose did not change that of control rats. Conclusion: These results indicates that CDDP enhances the increase in blood ammonia level by glutamine supplementation without correlating with primary parameters for hepatic/renal dysfunction.

scholarly journals An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Sayed Yossef ◽  
Frances Clark ◽  
Sarah S. Bubeck ◽  
John Abernethy ◽  
Thomas Bayne ◽  
...  
Keyword(s):  
Bacillus Subtilis ◽  
Hepatic Encephalopathy ◽  
Pilot Study ◽  
Oral Formulation ◽  
Ammonia Level ◽  
Blood Ammonia ◽  
Probiotic Group ◽  
Blood Ammonia Level ◽  
Study Product ◽  
The Mean

Background. Hepatic encephalopathy often results in high blood ammonia levels because of inefficient ammonia processing by the liver. Lactulose treatment promotes the growth of urease-producing gut bacteria and a reduced colon pH, thus reducing blood ammonia absorption. It is thought that probiotics as an add-on therapy may be beneficial. Patients and Methods. Bacillus subtilis HU58 was tested for safety and tolerability in patients with hepatic encephalopathy taking lactulose in this double-bind, placebo-controlled, 4-week pilot study. Study participants received one dose of B. subtilis HU58 or placebo (orally) for the first five days and two daily doses thereafter. Participants were monitored for safety and blood ammonia levels. Results. Forty patients participated (placebo, 11; probiotic, 29). Baseline characteristics were generally comparable; the mean baseline blood ammonia level was somewhat higher in the probiotic group. Mild or moderate treatment-emergent adverse events (TEAEs) were reported in 27.3% and 17.2% of patients in the placebo and probiotic groups, respectively; no severe TEAEs were reported. One patient (9.1%) taking placebo and two (6.9%) taking the probiotic experienced serious TEAEs (SAEs); none resulted in study discontinuation and all were considered to have no/unlikely relationship to the study product. There were no significant differences in the mean percent change (MPC) of blood ammonia levels between groups, though the probiotic group exhibited a trend toward a milder increase. Stratification of the probiotic group by baseline blood ammonia level (>60 μg/dL and ≤60 μg/dL) resulted in a significantly reduced MPC in the >60 μg/dL subgroup (MPC (SD); ≤60 μg/dL (n = 14), 35.3% (73.3); >60 μg/dL (n = 14), −26.5% (24.4); p=0.0087). Conclusions. Daily treatment with oral B. subtilis HU58 was safe and well tolerated over a 4-week period in patients with hepatic encephalopathy, and a significantly reduced MPC of blood ammonia level was observed in patients with a baseline level >60 µg/dL.

Blood Ammonia Level during Valproic Acid Therapy

1986 ◽  
Vol 40 (4) ◽  
pp. 663-668 ◽  
Author(s):  
Toshiaki Kugoh ◽  
Mitsutoshi Yamamoto ◽  
Kiyoshi Hosokawa
Keyword(s):  
Valproic Acid ◽  
Ammonia Level ◽  
Blood Ammonia ◽  
Acid Therapy ◽  
Valproic Acid Therapy ◽  
Blood Ammonia Level
Sign in / Sign up

Export Citation Format

Share Document